Clinical and genetic characteristics of 251 consecutive patients with macular and cone/cone-rod dystrophy.
Johannes BirtelTobias EisenbergerMartin GliemPhilipp L MüllerPhilipp HerrmannChristian BetzDiana ZahnleiterChristine NeuhausSteffen LenznerFrank G HolzElisabeth MangoldHanno J BolzPeter Charbel IssaPublished in: Scientific reports (2018)
Macular and cone/cone-rod dystrophies (MD/CCRD) demonstrate a broad genetic and phenotypic heterogeneity, with retinal alterations solely or predominantly involving the central retina. Targeted next-generation sequencing (NGS) is an efficient diagnostic tool for identifying mutations in patient with retinitis pigmentosa, which shows similar genetic heterogeneity. To detect the genetic causes of disease in patients with MD/CCRD, we implemented a two-tier procedure consisting of Sanger sequencing and targeted NGS including genes associated with clinically overlapping conditions. Disease-causing mutations were identified in 74% of 251 consecutive MD/CCRD patients (33% of the variants were novel). Mutations in ABCA4, PRPH2 and BEST1 accounted for 57% of disease cases. Further mutations were identified in CDHR1, GUCY2D, PROM1, CRX, GUCA1A, CERKL, MT-TL1, KIF11, RP1L1, MERTK, RDH5, CDH3, C1QTNF5, CRB1, JAG1, DRAM2, POC1B, NPHP1 and RPGR. We provide detailed illustrations of rare phenotypes, including autofluorescence and optical coherence tomography imaging. Targeted NGS also identified six potential novel genotype-phenotype correlations for FAM161A, INPP5E, MERTK, FBLN5, SEMA4A and IMPDH1. Clinical reassessment of genetically unsolved patients revealed subgroups with similar retinal phenotype, indicating a common molecular disease cause in each subgroup.
Keyphrases
- optical coherence tomography
- diabetic retinopathy
- end stage renal disease
- copy number
- newly diagnosed
- single cell
- genome wide
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- molecular dynamics
- gene expression
- dna methylation
- patient reported outcomes
- drug delivery
- climate change
- open label
- risk assessment
- double blind
- cell free